{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:42:02Z","timestamp":1777480922941,"version":"3.51.4"},"reference-count":55,"publisher":"SAGE Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CBM"],"published-print":{"date-parts":[[2023,12,15]]},"abstract":"<jats:p>BACKGROUND: Although there are many treatments for Multiple myeloma (MM), patients with MM still unable to escape the recurrence and aggravation of the disease. OBJECTIVE: We constructed a risk model based on genes closely associated with MM prognosis to predict its prognostic value. METHODS: Gene function enrichment and signal pathway enrichment analysis, Least Absolute Shrinkage and Selection Operator (LASSO) regression analysis, univariate and multivariate Cox regression analysis, Kaplan-Meier (KM) survival analysis and Receiver Operating Characteristic (ROC) analysis were used to identify the prognostic gene signature for MM. Finally, the prognostic gene signature was validated using the Gene Expression Omnibus (GEO) database. RESULTS: Thirteen prognostic genes were screened by univariate Cox analysis and LASSO regression analysis. Multivariate Cox analysis revealed risk score to be an independent prognostic factor for patients with MM [Hazard Ratio (HR) = 2.564, 95% Confidence Interval (CI) = 2.223\u20132.958, P&lt; 0.001]. The risk score had a high level of predictive value according to ROC analysis, with an area under the curve (AUC) of 0.744. CONCLUSIONS: The potential prognostic signature of thirteen genes were assessed and a risk model was constructed that significantly correlated with prognosis in MM patients.<\/jats:p>","DOI":"10.3233\/cbm-230115","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T11:18:00Z","timestamp":1699960680000},"page":"583-593","source":"Crossref","is-referenced-by-count":2,"title":["Comprehensive analysis of thirteen-gene panel with prognosis value in Multiple Myeloma"],"prefix":"10.1177","volume":"38","author":[{"given":"Tingting","family":"Zheng","sequence":"first","affiliation":[{"name":"School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China"},{"name":"School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panpan","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China"},{"name":"School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanlin","family":"Xu","sequence":"additional","affiliation":[{"name":"The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peijun","family":"Jia","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yating","family":"Li","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaming","family":"Cao","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanxin","family":"Li","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazhe","family":"Zhen","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijie","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangfeng","family":"Du","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxin","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"issue":"Suppl 1","key":"10.3233\/CBM-230115_ref1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.2586","article-title":"Multiple myeloma: Every year a new standard?","volume":"37","author":"Rajkumar","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.3233\/CBM-230115_ref2","doi-asserted-by":"crossref","first-page":"1069360","DOI":"10.3389\/fimmu.2022.1069360","article-title":"Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modern-era therapy: A real-life study","volume":"13","author":"Debureaux","year":"2022","journal-title":"Front Immunol"},{"key":"10.3233\/CBM-230115_ref3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12032-022-01651-w","article-title":"In silico bioinformatics analysis for identification of differentially expressed genes and therapeutic drug molecules in Glucocorticoid-resistant Multiple myeloma","volume":"39","author":"Ghosal","year":"2022","journal-title":"Med Oncol"},{"key":"10.3233\/CBM-230115_ref4","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1172\/JCI129205","article-title":"Immunotherapy of multiple myeloma","volume":"130","author":"Minnie","year":"2020","journal-title":"J Clin Invest"},{"key":"10.3233\/CBM-230115_ref5","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with high-risk cytogenetics and its treatment approach","volume":"115","author":"Hanamura","year":"2022","journal-title":"Int J Hematol"},{"key":"10.3233\/CBM-230115_ref6","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/ajh.26161","article-title":"Current approaches to management of high-risk multiple myeloma","volume":"96","author":"Goldman-Mazur","year":"2021","journal-title":"Am J Hematol"},{"key":"10.3233\/CBM-230115_ref7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-022-00679-5","article-title":"High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions","volume":"12","author":"Hagen","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.3233\/CBM-230115_ref8","doi-asserted-by":"crossref","first-page":"102284","DOI":"10.1016\/j.ctrv.2021.102284","article-title":"Roadmap to cure multiple myeloma","volume":"100","author":"Rodriguez-Otero","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.3233\/CBM-230115_ref9","doi-asserted-by":"crossref","unstructured":"E. Flynt, K. Bisht, V. Sridharan, M. Ortiz, F. Towfic and A. Thakurta, Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma, Cells 9 (2020).","DOI":"10.3390\/cells9020287"},{"key":"10.3233\/CBM-230115_ref10","doi-asserted-by":"crossref","first-page":"4198673","DOI":"10.1155\/2018\/4198673","article-title":"The Role of (18)F-FDG PET\/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie-Salmon Plus and Other Staging Systems","volume":"2018","author":"Deng","year":"2018","journal-title":"Contrast Media Mol Imaging"},{"key":"10.3233\/CBM-230115_ref11","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/leu.2009.61","article-title":"Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant","volume":"23","author":"Hari","year":"2009","journal-title":"Leukemia"},{"key":"10.3233\/CBM-230115_ref12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4274\/tjh.galenos.2020.2020.0115","article-title":"Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation","volume":"38","author":"Ciftciler","year":"2021","journal-title":"Turk J Haematol"},{"key":"10.3233\/CBM-230115_ref13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13045-021-01162-7","article-title":"Prognostic and predictive biomarker developments in multiple myeloma","volume":"14","author":"Wallington-Beddoe","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.3233\/CBM-230115_ref14","doi-asserted-by":"crossref","unstructured":"A.M. Soliman, S. Das and S.L. Teoh, Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis, Int J Mol Sci 22 (2021).","DOI":"10.3390\/ijms22147470"},{"key":"10.3233\/CBM-230115_ref15","doi-asserted-by":"crossref","first-page":"3307873","DOI":"10.1155\/2022\/3307873","article-title":"Increased Expression of SETDB1 Predicts Poor Prognosis in Multiple Myeloma","volume":"2022","author":"Xiang","year":"2022","journal-title":"Biomed Res Int"},{"key":"10.3233\/CBM-230115_ref16","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the Xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.3233\/CBM-230115_ref17","doi-asserted-by":"crossref","first-page":"665173","DOI":"10.3389\/fgene.2021.665173","article-title":"Identification and Validation of a Novel RNA-Binding Protein-Related Gene-Based Prognostic Model for Multiple Myeloma","volume":"12","author":"Wang","year":"2021","journal-title":"Front Genet"},{"key":"10.3233\/CBM-230115_ref18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41598-021-03980-8","article-title":"Integrated bioinformatics and network pharmacology to identify the therapeutic target and molecular mechanisms of Huangqin decoction on ulcerative Colitis","volume":"12","author":"Wu","year":"2022","journal-title":"Sci Rep"},{"key":"10.3233\/CBM-230115_ref19","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/16078454.2022.2040123","article-title":"Comprehensive bioinformatics analysis reveals the hub genes and pathways associated with multiple myeloma","volume":"27","author":"Zhao","year":"2022","journal-title":"Hematology"},{"key":"10.3233\/CBM-230115_ref20","doi-asserted-by":"crossref","unstructured":"P. Chen, J. Cao, L. Chen, G. Gao, Y. Xu, P. Jia, Y. Li, Y. Li, J. Du, S. Zhang and J. Zhang, Prognostic value of an eighteen-genes panel in acute myeloid leukemia by analyzing TARGET and TCGA databases, Cancer Biomark (2023).","DOI":"10.3233\/CBM-220179"},{"key":"10.3233\/CBM-230115_ref21","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1186\/s12885-020-07393-0","article-title":"HLA-DPA1 gene is a potential predictor with prognostic values in multiple myeloma","volume":"20","author":"Yang","year":"2020","journal-title":"BMC Cancer"},{"key":"10.3233\/CBM-230115_ref22","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/16078454.2021.1943617","article-title":"Identification of hub genes with prognostic values in multiple myeloma by bioinformatics analysis","volume":"26","author":"Yang","year":"2021","journal-title":"Hematology"},{"key":"10.3233\/CBM-230115_ref23","doi-asserted-by":"crossref","unstructured":"G. Di Conza and P.C. Ho, ER Stress Responses: An Emerging Modulator for Innate Immunity, Cells 9 (2020).","DOI":"10.3390\/cells9030695"},{"key":"10.3233\/CBM-230115_ref24","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1182\/blood-2018-10-880831","article-title":"High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma","volume":"133","author":"Thakurta","year":"2019","journal-title":"Blood"},{"key":"10.3233\/CBM-230115_ref25","doi-asserted-by":"crossref","unstructured":"C. Kim and B. Kim, Anti-Cancer Natural Products and Their Bioactive Compounds Inducing ER Stress-Mediated Apoptosis: A Review, Nutrients 10 (2018).","DOI":"10.3390\/nu10081021"},{"key":"10.3233\/CBM-230115_ref26","doi-asserted-by":"crossref","first-page":"e1534664","DOI":"10.1080\/2162402X.2018.1534664","article-title":"Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5","volume":"8","author":"Carlsten","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.3233\/CBM-230115_ref27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fcell.2019.00050","article-title":"Immunogenic Cell Death and Immunotherapy of Multiple Myeloma","volume":"7","author":"Serrano-Del Valle","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"10.3233\/CBM-230115_ref28","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7861\/clinmedicine.19-1-58","article-title":"Haematology: multiple myeloma","volume":"19","author":"Medical Masterclass","year":"2019","journal-title":"Clin Med (Lond)"},{"key":"10.3233\/CBM-230115_ref29","doi-asserted-by":"crossref","unstructured":"K.M. Lodge, A.S. Cowburn, W. Li and A.M. Condliffe, The Impact of Hypoxia on Neutrophil Degranulation and Consequences for the Host, Int J Mol Sci 21 (2020).","DOI":"10.3390\/ijms21041183"},{"key":"10.3233\/CBM-230115_ref30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/ard.54.1.33","article-title":"Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid","volume":"54","author":"van Leeuwen","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.3233\/CBM-230115_ref31","doi-asserted-by":"crossref","first-page":"6574491","DOI":"10.1155\/2021\/6574491","article-title":"Identification of Metabolism-Related Genes Influencing Prognosis of Multiple Myeloma Patients","volume":"2021","author":"Wang","year":"2021","journal-title":"J Healthc Eng"},{"key":"10.3233\/CBM-230115_ref32","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1080\/16078454.2022.2068873","article-title":"Identification of key genes and miRNA-mRNA regulatory networks associated with bone marrow immune microenvironment regulations in multiple myeloma by integrative bioinformatics analysis","volume":"27","author":"Tuerxun","year":"2022","journal-title":"Hematology"},{"key":"10.3233\/CBM-230115_ref33","doi-asserted-by":"crossref","unstructured":"P. Chen, G. Gao, Y. Xu, P. Jia, Y. Li, Y. Li, J. Cao, J. Du, S. Zhang and J. Zhang, Novel gene signature reveals prognostic model in acute lymphoblastic leukemia, Frontiers in Cell and Developmental Biology 10 (2022).","DOI":"10.3389\/fcell.2022.1036312"},{"key":"10.3233\/CBM-230115_ref34","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ajh.25365","article-title":"Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma","volume":"94","author":"Binder","year":"2019","journal-title":"Am J Hematol"},{"key":"10.3233\/CBM-230115_ref35","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/bjh.16744","article-title":"Development of an RNA sequencing-based prognostic gene signature in multiple myeloma","volume":"192","author":"Zamani-Ahmadmahmudi","year":"2021","journal-title":"Br J Haematol"},{"key":"10.3233\/CBM-230115_ref36","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1186\/s12864-021-07895-6","article-title":"Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis","volume":"22","author":"Lin","year":"2021","journal-title":"BMC Genomics"},{"key":"10.3233\/CBM-230115_ref37","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s12957-022-02835-4","article-title":"Lymphadenectomy in ovarian cancers: a meta-analysis of hazard ratios from randomized clinical trials","volume":"20","author":"Purwar","year":"2022","journal-title":"World J Surg Oncol"},{"key":"10.3233\/CBM-230115_ref38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12874-017-0332-6","article-title":"Time-dependent ROC curve analysis in medical research: current methods and applications","volume":"17","author":"Kamarudin","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"10.3233\/CBM-230115_ref39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3348\/kjr.2004.5.1.11","article-title":"Receiver operating characteristic (ROC) curve: practical review for radiologists","volume":"5","author":"Park","year":"2004","journal-title":"Korean J Radiol"},{"key":"10.3233\/CBM-230115_ref40","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.3233\/CBM-230115_ref41","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.7150\/ijms.48244","article-title":"Identification of Key Genes and Pathways in Myeloma side population cells by Bioinformatics Analysis","volume":"17","author":"Yang","year":"2020","journal-title":"Int J Med Sci"},{"key":"10.3233\/CBM-230115_ref42","doi-asserted-by":"crossref","first-page":"5600190","DOI":"10.1155\/2022\/5600190","article-title":"Identification of Biomarkers Associated with Diagnosis of Osteoarthritis Patients Based on Bioinformatics and Machine Learning","volume":"2022","author":"Liang","year":"2022","journal-title":"J Immunol Res"},{"key":"10.3233\/CBM-230115_ref43","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front Immunol"},{"key":"10.3233\/CBM-230115_ref44","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"key":"10.3233\/CBM-230115_ref45","doi-asserted-by":"crossref","unstructured":"Z.L. Piedra-Quintero, Z. Wilson, P. Nava and M. Guerau-de-Arellano, CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity, Frontiers in Immunology 11 (2020).","DOI":"10.3389\/fimmu.2020.597959"},{"key":"10.3233\/CBM-230115_ref46","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological malignancies and beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol Rev"},{"key":"10.3233\/CBM-230115_ref47","doi-asserted-by":"crossref","unstructured":"I. Saltarella, V. Desantis, A. Melaccio, A.G. Solimando, A. Lamanuzzi, R. Ria, C.T. Storlazzi, M.A. Mariggio, A. Vacca and M.A. Frassanito, Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma, Cells 9 (2020).","DOI":"10.3390\/cells9010167"},{"key":"10.3233\/CBM-230115_ref48","doi-asserted-by":"crossref","unstructured":"A. Gozzetti, S. Ciofini, M. Simoncelli, A. Santoni, P. Pacelli, D. Raspadori and M. Bocchia, Anti CD38 monoclonal antibodies for multiple myeloma treatment, Human Vaccines & Immunotherapeutics 18 (2022).","DOI":"10.1080\/21645515.2022.2052658"},{"key":"10.3233\/CBM-230115_ref49","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1182\/blood.2021012448","article-title":"SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma","volume":"139","author":"Kassem","year":"2022","journal-title":"Blood"},{"key":"10.3233\/CBM-230115_ref50","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1158\/1078-0432.CCR-21-1621","article-title":"BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression","volume":"27","author":"Xing","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.3233\/CBM-230115_ref51","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"10.3233\/CBM-230115_ref52","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"key":"10.3233\/CBM-230115_ref53","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1182\/blood.2020005885","article-title":"Progression signature underlies clonal evolution and dissemination of multiple myeloma","volume":"137","author":"Shen","year":"2021","journal-title":"Blood"},{"key":"10.3233\/CBM-230115_ref54","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.21037\/atm-22-2656","article-title":"Bioinformatics analysis of the prognostic biomarkers and predictive accuracy of differentially expressed genes in high-risk multiple myeloma based on Gene Expression Omnibus database mining","volume":"10","author":"Du","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.3233\/CBM-230115_ref55","first-page":"470","article-title":"The Diagnosis and Treatment of Multiple Myeloma","volume":"113","author":"Gerecke","year":"2016","journal-title":"Dtsch Arztebl Int"}],"container-title":["Cancer Biomarkers"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/CBM-230115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:10:29Z","timestamp":1777385429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.medra.org\/servlet\/aliasResolver?alias=iospress&doi=10.3233\/CBM-230115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":55,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/cbm-230115","relation":{},"ISSN":["1875-8592","1574-0153"],"issn-type":[{"value":"1875-8592","type":"electronic"},{"value":"1574-0153","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,15]]}}}